McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« Apotex Tries Again for DJ Jurisdiction Based on Patent Listing in Orange Book | Main | Pfizer Wins Another Round in Norvasc Case as Synthon's Patents Are Found Unenforceable »

February 01, 2007

Senators Reintroduce Bill to Ban Authorized Generics

Senator Jay Rockefeller (D-WV) has introduced S. 438, "The Fair Prescription Drug Act of 2007," which would ban the sale of authorized generic drugs during an ANDA applicant's 180-day exclusivity period.  The bill is cosponsored by Senators Kohl (D-WI), Leahy, (D-VT), and Schumer (D-NY).  The same bill was proposed last year as S. 3695.  Senator Kohl expressed optimism that the bill would have better prospects this time around--and it just might, given that the Democrats now control Congress.

RELATED READING:

Posted by in Authorized Generics |

Comments

The comments to this entry are closed.